Research programme: ion channel modulators - Bristol-Myers Squibb/Icagen

Drug Profile

Research programme: ion channel modulators - Bristol-Myers Squibb/Icagen

Alternative Names: Atrial fibrillation therapy - Icagen

Latest Information Update: 11 Feb 2008

Price : $50

At a glance

  • Originator Icagen
  • Developer Bristol-Myers Squibb; Icagen
  • Class Small molecules
  • Mechanism of Action Ion channel modulators; Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 08 Aug 2007 Bristol-Myers Squibb discontinues its development in this research programme
  • 10 Aug 2006 Preclinical trials in Atrial fibrillation in USA (unspecified route)
  • 21 Nov 2005 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top